Announcements Trials
Browse Landscape

Phase

Phase 2 13Phase 3 8Phase 1/2 4Phase NA 2Phase 4 2Phase 2/3 1Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Warts 1Recurrence 1Neutropenia 1Multiple Myeloma 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Leukemia 1Infections 1Immunologic Deficiency Syndromes 1Hodgkin Disease 1Hematologic Neoplasms 1Febrile Neutropenia 1Congenital Abnormalities 1Breast Neoplasms 1Agammaglobulinemia 1

Interventions

Capecitabine 16Paclitaxel 12Docetaxel 10Cyclophosphamide 10Epirubicin 8Gemcitabine 7Letrozole 6Doxorubicin 6Carboplatin 6Trastuzumab 5Vinorelbine 4Cisplatin 4pertuzumab 3exemestane 3Neoadjuvant Therapy 3Drug Therapy 3Ado-Trastuzumab Emtansine 3AC protocol 3130-nm albumin-bound paclitaxel 3apatinib 2Zoledronic Acid 2Thiotepa 2Taxes 2Tamoxifen 2Standard of Care 2Radiosurgery 2Melatonin 2Lapatinib 2Injections 2Goserelin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Breast Neoplasms × Granulocyte Colony-Stimulating Factor × Clear all
NCT00169104 2018-07-20

Effects of Granulocyte Colony-stimulating Factor (G-CSF), Trastuzumab, and Vinorelbine on Immune Cell Function

Dartmouth-Hitchcock Medical Center

Phase 2/3 Terminated
23 enrolled 10 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡